dokumendiregister.ee
OtsingAsutusedMCP
Otsing›Sotsiaalministeerium
Muu lepingAvalik

Konsortsiumilepe

Sotsiaalministeerium · 20. november 2020
Viit
1.1-5/1260-1
Registreeritud
20. november 2020
Dokumendi liik
Muu leping
Funktsioon
1.1 Juhtimine, arendus ja planeerimine
Sari
1.1-5 Riigisisese ja rahvusvahelise koostöö edendamise kokkulepped (Arhiiviväärtuslik)
Toimik
1.1-5
Vastutaja
Ivar Sikk (Sotsiaalministeerium, Kantsleri vastutusvaldkond, Sotsiaalala asekantsleri vastutusvaldkond, Hoolekande osakond)

Failid

  • 📎CA_JADECARE_Final Version_Signed.pdf2107 KB

Sisu (failidest)

JADECARE Consortium Agreement - Final version , 2020-10-26 CONSORTIUM AGREEMENT JOINT ACTION ON IMPLEMENTATION OF DIGITALLY ENABLED INTEGRATED PERSON-CENTERED CARE - JADECARE Bilbao, Basque Country-Spain October 26th 2020 1 / 47 JADECARE Consortium Agreement - Final version , 2020-10-26 Table of Content CONSORTIUM AGREEMENT ................................................................................................................ 3 1 Section: Definitions ....................................................................................................................... 4 2 Section: Purpose ........................................................................................................................... 5 3 Section: Entry into force, duration and termination .................................................................. 5 4 Section: Responsibilities of Beneficiaries .................................................................................. 6 5 Section: Liability towards each other .......................................................................................... 8 6 Section: Governance structure .................................................................................................... 9 7 Section: Financial provisions..................................................................................................... 18 8 Section: Results........................................................................................................................... 19 9 Section: Access Rights ............................................................................................................... 22 10 Section: Non-disclosure of information .................................................................................... 24 11 Section: Miscellaneous ............................................................................................................... 26 12 Section Signatures ...................................................................................................................... 28 Attachment 1: Accession document ................................................................................................. 45 Attachment 2: List of Affiliated Entities ............................................................................................ 46 2 / 47 JADECARE Consortium Agreement - Final version , 2020-10-26 CONSORTIUM AGREEMENT This Consortium Agreement is a private reciprocal agreement between the beneficiaries of the Joint Action JADECARE, to set out the rights and obligations amongst themselves. (It does not involve the European Commission nor CHAFEA). It complements the Grant Agreement and does not contain any provision contrary to it. It must be signed by all beneficiaries. THIS CONSORTIUM AGREEMENT is based upon the Grant Agreement with the Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) for the Joint Action entitled “Joint Action on implementation of Digitally Enabled integrated person-centered CARE – JADECARE” Grant Agreement number 951442, and is effective as of 01 October 2020, hereinafter referred to as “the starting date of the Joint Action” and “Effective Date”. BETWEEN: 1. ASOCIACIÓN INSTITUTO DE INVESTIGACIÓN EN SERVICIOS DE SALUD- KRONIKGUNE (KG), the coordinator, 2. MINISTRY OF CIVIL AFFAIRS (MCA), Bosnia and Herzegovina, 3. HRVATSKI ZAVOD ZA JAVNO ZDRAVSTVO (CIPH), Croatia, 4. MINISTERSTVO ZDRAVOTNICTVI CESKE REPUBLIKY (MZCR), Czech Republic, 5. REGION NORDJYLLAND (NORTH DENMARK REGION) (RND), Denmark, 6. SOTSIAALMINISTEERIUM (MSAE), Estonia, 7. EUROMETROPOLE DE STRASBOURG (EUSTRAS), France, 8. BEHOERDE FUER ARBEIT, GESUNDHEIT, SOZIALES, FAMILIE UND INTEGRATION HAMBURG (BAGSFI), Germany, 9. 4I DIOIKISI YGEIONOMIKIS PERIFEREIAS MAKEDONIAS KAI THRAKIS (4THYPE), Greece, 10. ALLAMI EGESZSEGUGYI ELLATO KOZPONT (AEEK), Hungary, 11. AGENZIA NAZIONALE PER I SERVIZI SANITARI REGIONALI (AGENAS), Italy, 12. NACIONALAIS VESELIBAS DIENESTS (NVD), Latvia, 13. LIETUVOS RESPUBLIKOS SVEIKATOS APSAUGOS MINISTERIJA (LR SAM), Lithuania, 14. ADMINISTRACAO CENTRAL DO SISTEMA DESAUDE IP (ACSS), Portugal, 15. MINISTARSTVO ZDRAVLJA (MoHRS), Serbia, 16. NACIONALNI INSTITUT ZA JAVNO ZDRAVJE (NIJZ), Slovenia, 17. REGIONAL HEALTH AND SOCIAL CARE BOARD (HSCB), United Kingdom, hereinafter, jointly or individually, referred to as “Beneficiaries” or “Beneficiary” relating to the Joint Action entitled “JOINT ACTION ON IMPLEMENTATION OF DIGITALLY ENABLED INTEGRATED PERSON-CENTERED CARE” in short JADECARE hereinafter referred to as “Joint Action (JA)” 3 / 47 JADECARE Consortium Agreement - Final version , 2020-10-26 WHEREAS: The Beneficiaries, having considerable experience in the field concerned, have submitted a proposal for the Joint Action to CHAFEA as part of the 3rd. EU Health Programme (2014- 2020). The Competent Authorities wish to specify or supplement binding commitments among themselves in addition to the provisions of the specific Grant Agreement to be signed by the Competent Authorities and the Funding Authority (hereinafter “Grant Agreement”). The Beneficiaries are aware that this Consortium Agreement is based upon the DESCA model consortium agreement. NOW, THEREFORE, IT IS HEREBY AGREED AS FOLLOWS: 1 Section: Definitions 1.1 Definitions Words beginning with a capital letter shall have the meaning defined either herein or in the Rules for Participation or in the Grant Agreement including its Annexes. 1.2 Additional Definitions “Beneficiary or Beneficiaries” means a beneficiary or the beneficiaries to this Consortium Agreement also identified as the beneficiaries to the Grant Agreement. “Coordination Team”. The Coordination Team (CT) forms an integral part of the Coordinator and both terms will be used interchangeably. “Competent Authority” (CA) means the central authority of a Member State competent for health/specific (public) health topic or any other authority to which that competence has been conferred; it shall also include, where appropriate, the corresponding authority of a third country. A Competent Authority can also be one at regional level, depending on the governance structure of the Member State/third country. “Affiliated Entity” (AE) - entities affiliated to the nominated Competent Authorities: these are organizations that have a distinct legal personality but are linked to the nominated Competent Authority. “Consortium Body“ means any management body described in the Governance Structure section of this Consortium Agreement. “Consortium Plan” means the description of the action and the related agreed budget as first defined in the Grant Agreement and which may be updated by the General Assembly. "Funding Authority," means the body awarding the grant for the Joint Action. 4 / 47 JADECARE Consortium Agreement - Final version , 2020-10-26 “Force Majeure” “Force Majeure” means any one or more events beyond the reasonable control of the relevant Party which occur after the date of signing of this Consortium Agreement, were not reasonably foreseeable at the time of signing of this Consortium Agreement, and the effects of which are not capable of being overcome without unreasonable expense and/or unreasonable loss of time to the Party concerned. Force Majeure events shall include (without limitation) war, civil unrest, acts of government, natural disasters, exceptional weather conditions, breakdown or general unavailability of transport facilities, accidents, fire, explosions, and general shortages of energy. “Defaulting Beneficiary” means a Beneficiary which the General Assembly has identified to be in breach of this Consortium Agreement and/or the Grant Agreement as specified in Section 4.2 of this Consortium Agreement. “Needed” means: For the implementation of the Joint Action: Access Rights are Needed if, without the grant of such Access Rights, carrying out the tasks assigned to the recipient Beneficiary would be technically or legally impossible, significantly delayed, or require significant additional financial or human resources. For Exploitation of own Results: Access Rights are Needed if, without the grant of such Access Rights, the Exploitation of own Results would be technically or legally impossible. 2 Section: Purpose The purpose of this Consortium Agreement is to specify with respect to the Joint Action the relationship among the Beneficiaries, in particular concerning the organisation of the work between the Beneficiaries, the management of the Joint Action and the rights and obligations of the Beneficiaries concerning inter alia liability, Access Rights and dispute resolution. 3 Section: Entry into force, duration and termination 3.1 Entry into force An entity becomes a Beneficiary to this Consortium Agreement upon signature of this Consortium Agreement by a duly authorized representative. This Consortium Agreement shall have effect from the Effective Date identified in the Grant Agreement. A new entity becomes a Beneficiary to the Consortium Agreement upon signature of the accession document (Attachment 1) by the new Beneficiary and the Coordinator. Such accession shall have effect from the date identified in the accession document. 3.2 Duration and termination This Consortium Agreement shall continue in full force and effect until complete fulfilment of all obligations undertaken by the Beneficiaries under the Grant Agreement and under this Consortium Agreement. 5 / 47 JADECARE Consortium Agreement - Final version , 2020-10-26 However, this Consortium Agreement or the participation of one or more Beneficiaries may be terminated in accordance with the terms of this Consortium Agreement. If - the Grant Agreement is not signed by the Funding Authority or a Beneficiary, or - the Grant Agreement is terminated, or - a Beneficiary's participation in the Grant Agreement is terminated, this Consortium Agreement shall automatically terminate in respect of the affected Beneficiary/ies, subject to the provisions surviving the expiration or termination under Section 3 of this Consortium Agreement. 3.3 Survival of rights and obligations The provisions relating to Access Rights, Dissemination and Confidentiality, for the time period mentioned therein, as well as for liability, applicable law and settlement of disputes shall survive the expiration or termination of this Consortium Agreement. Termination shall not affect any rights or obligations of a Beneficiary leaving the Consortium incurred prior to the date of termination, unless otherwise agreed between the General Assembly and the leaving Beneficiary. This includes the obligation to provide all input, deliverables and documents for the period of its participation. 4 Section: Responsibilities of Beneficiaries 4.1 General principles Each Beneficiary undertakes to take part in the efficient implementation of the Joint Action, and to cooperate, perform and fulfil, promptly and on time, all of its obligations under the Grant Agreement and this Consortium Agreement as may be reasonably required from it and in a manner of good faith as prescribed by Belgian law. Each Beneficiary undertakes to notify promptly, in accordance with the governance structure of the Joint Action, any significant information, fact, problem or delay likely to affect the Joint Action. Each Beneficiary shall promptly provide all information reasonably required by a Consortium Body or by the Coordinator to carry out its tasks. Each Beneficiary shall take reasonable measures to ensure the accuracy of any information or materials it supplies to the other Beneficiaries. 4.2 Breach In the event that a responsible Consortium Body identifies a breach by a Beneficiary of its obligations under this Consortium Agreement or the Grant Agreement (e.g. improper implementation of the Joint Action), the Coordinator or, if the Coordinator is in breach of its obligations, the Beneficiary appointed by the General Assembly, will give formal notice to such Beneficiary requiring that such breach will be remedied within 30 calendar days from the date of receipt of the written notice by the Beneficiary. If such breach is substantial, as mention on the Grant Agreement Article 7, and is not remedied within that period or is not capable of remedy, the General Assembly may decide to declare the Beneficiary to be a Defaulting Beneficiary and to decide on the consequences thereof that may include termination of its participation. 6 / 47 JADECARE Consortium Agreement - Final version , 2020-10-26 4.3 Involvement of third Beneficiaries A Beneficiary that enters into a subcontract or otherwise involves third Beneficiaries (including but not limited to Affiliated Entities) in the Joint Action remains responsible for carrying out its relevant part of the Joint Action and for such Affiliated Entity’s compliance with the provisions of this Consortium Agreement and of the Grant Agreement. It has to ensure that the involvement of third Beneficiaries does not affect the rights and obligations of the other Beneficiaries under this Consortium Agreement and the Grant Agreement. 4.4 Affiliated entities With regards to affiliated entities, the following two options exist: 4.4.1 Affiliated entities to a beneficiary – legal or capital link According to article 122 of the Financial Regulation an entity affiliated to a "single" beneficiary (for Joint Actions - the competent authority) is an entity that fulfils the following conditions: It has a structural link with the "single" beneficiary, in particular a legal or capital link. In general, the notion of legal and capital link encompasses mainly two notions - control and membership. Control means that entities are directly or indirectly controlled by the beneficiary, under the same control as the beneficiary - or controlling the beneficiary. Membership, means that the beneficiary is defined as for example a network, federation, association in which the affiliated entities also participate. 4.4.2 Affiliated entities forming one "Sole beneficiary" as a single entity Article 122.1 of the Financial Regulation introduced the concept of "sole beneficiary": "Where several entities satisfy the criteria for being awarded a grant and together form one entity, that entity may be treated as the "sole beneficiary", including where the entity is specifically established for the purpose of implementing the action to be financed by the grant". The competent authority, acting as leader of or affiliated to the "sole beneficiary", must have been nominated by the participating country. The "sole beneficiary" may be legally established specifically for the purpose of the action. The "sole beneficiary" does not need to have a distinct legal personality. The affiliated entities forming the "sole beneficiary" should establish as appropriate internal arrangements setting out the functioning of the "sole beneficiary" and the role of each one. This internal arrangement may take the form of an internal co-operation agreement (national consortium agreement). In both above cases, only the leader of the sole beneficiary will sign the Joint Action Grant Agreement. 4.4.3 Legal commitment and responsibilities of the beneficiary and affiliated entities for both options a. The competent authority or beneficiary and its affiliated entities have to be identified in the Grant Agreement. b. The beneficiary is fully responsible for the implementation of the tasks assigned to its affiliated entities, from the operational and financial point of view. Therefore: They must inform of any change to the situation of their affiliates. 7 / 47 JADECARE Consortium Agreement - Final version , 2020-10-26 c. They are financially responsible for any amount that would have been paid as reimbursement of costs unduly declared by its affiliated entities. d. The beneficiary has obligations in connection to its affiliated entities, among others: Ensuring that the eligibility criteria applying to its own costs apply also to the costs incurred by its affiliated entities; Ensuring compliance of its affiliated entities with the rules applying to them on nonliability of the Commission, absence of conflict of interest, confidentiality, visibility of the Union and evaluation. e. A beneficiary cannot subcontract tasks to its affiliated entities or to the entities affiliated to another beneficiary in the same grant. This is considered like subcontracting activities between different beneficiaries of a grant and is forbidden by the Financial Regulation. 5 Section: Liability towards each other 5.1 No warranties In respect of any information or materials (incl. Results) supplied by one Beneficiary to another under the Joint Action, no warranty or representation of any kind is made, given or implied as to the sufficiency or fitness for purpose nor as to the absence of any infringement of any proprietary rights of third Beneficiaries. Therefore,  the recipient Beneficiary shall in all cases be entirely and solely liable for the use to which it puts such information and materials, and  no Beneficiary granting Access Rights shall be liable in case of infringement of proprietary rights of an Affiliated Entity resulting from any other Beneficiary (or its Affiliated Entities) exercising its Access Rights. 5.2 Limitations of contractual liability No Beneficiary shall be responsible to any other Beneficiary for any indirect or consequential loss or similar damage such as, but not limited to, loss of profit, loss of revenue or loss of contracts, provided such damage was not caused by a wilful act or by a breach of confidentiality. For any remaining contractual liability, a Beneficiary’s aggregate liability towards the other Beneficiaries collectively shall be limited to the Beneficiary’s share of the total costs of the Joint Action as identified in Annex 2 of the Grant Agreement provided such damage was not caused by a wilful act or gross negligence. The terms of this Consortium Agreement shall not be construed to amend or limit any Beneficiary’s statutory liability. 5.3 Damage caused to third Beneficiaries Each Beneficiary shall be solely liable for any loss, damage or injury to third Beneficiaries resulting from the performance of the said Beneficiary’s obligations by it or on its behalf under this Consortium Agreement or from its use of Results. 8 / 47 JADECARE Consortium Agreement - Final version , 2020-10-26 5.4 Force Majeure No Beneficiary shall be considered to be in breach of this Consortium Agreement if it is prevented from fulfilling its obligations under the Consortium Agreement by Force Majeure. Each Beneficiary will notify the competent Consortium Bodies of any Force Majeure without undue delay. If the consequences of Force Majeure for the Joint Action are not overcome within 6 weeks after such notification, the transfer of tasks - if any - shall be decided by the competent Consortium Bodies. 6 Section: Governance structure 6.1 General structure The organisational structure of the Consortium shall comprise the following Consortium Bodies: “General Assembly (GA)” as the ultimate decision-making body of the Consortium. “Steering Committee (SC)” as the supervisory body for the execution of the Joint Action which shall report to and be accountable to the General Assembly. The “Coordinator” is the legal entity acting as the intermediary between the Beneficiaries and the Funding Authority. The Coordinator shall, in addition to its responsibilities as a Beneficiary, perform the tasks assigned to it as described in the Grant Agreement and this Consortium Agreement. The “Coordination Team” is responsible for the achievement of the JA goals and the contractual obligations towards the European Commission, and provides global scientific and technical leadership, quality assurance policy and overall coordination of the joint action. The Coordination Team is formed by the JA Coordinator supported by the Scientific Coordinator, the Project Manager and the Financial Manager. Coordination and implementation roles and activities in the Joint Action are performed by CAs (as Leading Beneficiaries (LB)), and AEs. AEs can act as Leading Executive Organisations (LEO) and Co-Leading Executive Organisations. CAs and AEs are responsible for Work Packages and/or Tasks and contribute to the Deliverables and Milestones as described in the JADECARE Joint Action. The “Work Package lead (WPL)” is formed by the Lead Beneficiary (LB), the Leading Executive Organization (LEO) and the co-Leading Executive Organisation. It is responsible for the day-to-day management and coordination of the activities included in their respective work packages as defined in the Grant Agreement, and will be able to raise proposals to the SC regarding effort and budget redistribution, and re-assignment of roles and responsibilities within their respective WPs. “Next Adopters Working Groups (NAWG)” are in charge for the implementation of the Local Good Practices, led by the representative of the corresponding Competent Authority or Affiliated Entity. “Policy Board (PB)” is responsible for giving input to sustainability plans from the focus of policy, and the definition of core messages to support evidence-based policy making with respect to sustainability of JADECARE results. 9 / 47 JADECARE Consortium Agreement - Final version , 2020-10-26 6.2 General operational procedures for all Consortium Bodies 6.2.1 Representation in meetings Any Beneficiary which is a member of a Consortium Body (hereinafter referred to as "Member"): - should be present or represented at plenary meetings, GA meetings and Stakeholder Forum. - may appoint a substitute or a proxy to attend and vote at any meeting; and shall participate in a cooperative manner in the meetings. Work Package Leads should: - be present or represented at plenary meetings and SC meetings. - be present or represented at Work Package meetings in which they participate. - may appoint a substitute or a proxy to attend a meeting; and shall participate in a cooperative manner in the meetings. CAs and AEs should: - be present or represented at Work Package meetings in which they participate. - may appoint a substitute or a proxy to attend a meeting; and shall participate in a cooperative manner in the meetings. 6.2.2 Preparation and organisation of meetings The Consortium Bodies will prepare and organize meetings according to the general rules below. The General Assembly and the Steering Committee will comply with the specified deadlines and rules. 6.2.2.1 Convening meetings The chairperson of a Consortium Body shall convene meetings of that Consortium Body. Ordinary Extraordinary meeting meeting General At least once At any time upon written request of the Coordinator, Assembly a year Steering Committee or 1/3 of the Members of the General Assembly Steering At least once At any time upon written request of the Coordinator or any Committee a month via 1/3 of the Members of the Steering Committee tele or web- conferencing and at least once a year face to face. 10 / 47 JADECARE Consortium Agreement - Final version , 2020-10-26 6.2.2.2 Notice of a meeting The chairperson of a Consortium Body shall give notice in writing of a meeting to each Member of that Consortium Body as soon as possible and no later than the minimum number of days preceding the meeting as indicated below. Ordinary meeting Extraordinary meeting General Assembly 45 calendar days 15 calendar days Steering 14 calendar days 7 calendar days Committee 6.2.2.3 Sending the agenda The chairperson of a Consortium Body shall prepare and send each Member of that Consortium Body a written (original) agenda no later than the minimum number of days preceding the meeting as indicated below. General Assembly 21 calendar days, 10 calendar days for an extraordinary meeting Steering Committee 7 calendar days 6.2.2.4 Adding agenda items: Any agenda item requiring a decision by the Members of a Consortium Body must be identified as such on the agenda. Any Member of a Consortium Body may add an item to the original agenda by written notification to all of the other Members of that Consortium Body up to the minimum number of days preceding the meeting as indicated below. General Assembly 14 calendar days, 7 calendar days for an extraordinary meeting Steering Committee 2 calendar days 6.2.2.5 During a meeting, the Members of a Consortium Body present or represented can unanimously agree to add a new item to the original agenda. 6.2.2.6 Meetings of each Consortium Body may also be held by teleconference or other telecommunication means. 6.2.2.7 Decisions will only be binding once the relevant part of the Minutes has been accepted according to Section 6.2.5. 6.2.2.8 Any decision may also be taken without a meeting if the Coordinator circulates to all Members of the Consortium Body a written document, which is then agreed by the defined majority (see Section 6.2.3) of all Members of the Consortium Body. Such document shall include the deadline for responses. Decisions taken without a meeting shall be considered as accepted if, within the period set out in article 6.2.4.4, no Member has sent an objection in writing to the chairperson. The decisions will be binding after the chairperson sends to all Members of the Consortium Body and to the Coordinator a written notification of this acceptance. 11 / 47 JADECARE Consortium Agreement - Final version , 2020-10-26 6.2.3 Voting rules and quorum 6.2.3.1 Each Consortium Body shall not deliberate and decide validly unless two-thirds (2/3) of its Members are present or represented (quorum). If the quorum is not reached, the chairperson of the Consortium Body shall convene another ordinary meeting within 15 calendar days. If in this meeting the quorum is not reached once more, the chairperson shall convene an extraordinary meeting, which shall be entitled to decide even if less than the quorum of Members are present or represented. 6.2.3.2 Voting rules means one vote per Competent Authority (CA). 6.2.3.3 A Beneficiary which the General Assembly has declared according to Section 4.2 to be a Defaulting Beneficiary may not vote. 6.2.3.4 Decisions shall be taken by a majority of two-thirds (2/3) of the votes cast. 6.2.4 Veto rights 6.2.4.1 A Member which can show that its own work, time for performance, costs, liabilities, intellectual property rights or other legitimate interests would be severely affected by a decision of a Consortium Body may exercise a veto with respect to the corresponding decision or relevant part of the decision. 6.2.4.2 When the decision is foreseen on the original agenda, a Member may veto such a decision during the meeting only. 6.2.4.3 When a decision has been taken on a new item added to the agenda before or during the meeting, a Member may veto such decision during the meeting and within 15 calendar days after the draft minutes of the meeting are sent. 6.2.4.4 When a decision has been taken without a meeting, a Member may veto such decision within 15 calendar days after written notification by the chairperson of the outcome of the vote. 6.2.4.5 In case of exercise of veto, the Members of the related Consortium Body shall make every effort to resolve the matter, which occasioned the veto to the general satisfaction of all its Members. 6.2.4.6 A Beneficiary may neither veto decisions relating to its identification to be in breach of its obligations nor to its identification as a Defaulting Beneficiary. The Defaulting Beneficiary may not veto decisions relating to its participation and termination in the consortium or the consequences of them. 12 / 47 JADECARE Consortium Agreement - Final version , 2020-10-26 6.2.4.7 A Beneficiary requesting to leave the consortium may not veto decisions relating thereto. 6.2.5 Minutes of meetings 6.2.5.1 The chairperson of a Consortium Body shall produce written minutes of each meeting, which shall be the formal record of all decisions taken. He/she shall send the draft minutes to all Members within 10 calendar days of the meeting. 6.2.5.2 The minutes shall be considered as accepted if, within 15 calendar days from sending, no Member has sent an objection in writing to the chairperson with respect to the accuracy of the draft of the minutes. 6.2.5.3 The chairperson shall send the accepted minutes to all the Members of the Consortium Body and to the Coordinator, who shall safeguard them. If requested the Coordinator shall provide authenticated duplicates to Beneficiaries. 6.3 Specific operational procedures for the Consortium Bodies 6.3.1 General Assembly In addition to the rules described in Section 6.2, the following rules apply: 6.3.1.1 Members 6.3.1.1.1 The General Assembly will be chaired by the Joint Action Coordinator and contain representatives from each of the Competent Authorities and their Affiliated entities. This plenary assembly will be the ultimate decision-making body in JADECARE. A general assembly of all entities with decision-making responsibility in matters affecting the overall project strategy, major work plan updates composition of the Consortium, effort and budget re-assignment. In the voting in the General Assembly, each Beneficiary/Competent Authority has one vote (hereinafter General Assembly Member). 6.3.1.1.2 Each General Assembly Member shall be deemed to be duly authorised to deliberate, negotiate and decide on all matters listed in Section 6.3.1.2. of this Consortium Agreement. 6.3.1.1.3 The Coordinator shall chair all meetings of the General Assembly, unless decided otherwise in a meeting of the General Assembly. 6.3.1.1.4 The Beneficiaries agree to abide by all decisions of the General Assembly. This does not prevent the Beneficiaries to submit a dispute to resolution in accordance with the provisions of Settlement of disputes in Section 11.8. 13 / 47 JADECARE Consortium Agreement - Final version , 2020-10-26 6.3.1.2 Decisions The General Assembly shall be free to act on its own initiative to formulate proposals and take decisions in accordance with the procedures set out herein. In addition, all proposals made by the Steering Committee shall also be considered and decided upon by the General Assembly. The following decisions shall be taken by the General Assembly: As regards content, finances and intellectual property rights  Proposals for changes to Annexes 1 and 2 of the Grant Agreement to be agreed by the Funding Authority  Changes to the Consortium Plan  Additions to Attachment 2 (Identified Affiliated Entities) As regards evolution of the consortium  Entry of a new Beneficiary to the consortium and approval of the settlement on the conditions of the accession of such a new Beneficiary  Withdrawal of a Beneficiary from the consortium and the approval of the settlement on the conditions of the withdrawal  Identification of a breach by a Beneficiary of its obligations under this Consortium Agreement or the Grant Agreement  Declaration of a Beneficiary to be a Defaulting Beneficiary  Remedies to be performed by a Defaulting Beneficiary  Termination of a Defaulting Beneficiary’s participation in the consortium and measures relating thereto  Proposal to the Funding Authority for a change of the Coordinator  Proposal to the Funding Authority for suspension of all or part of the Joint Action  Proposal to the Funding Authority for termination of the Joint Action and the Consortium Agreement As regards appointments On the basis of the Grant Agreement, the appointment if necessary of: - Steering Committee Members 6.3.2 Steering Committee In addition to the rules in Section 6.2, the following rules shall apply: 6.3.2.1 Members The Steering Committee shall consist of an operational body comprising the Coordination Team and the WP Leads (Lead Beneficiary, Leading and Co-Leading Executive Organisations) as a decision making body on daily running of the project, with prerogatives regarding minor updates, and effort/budget re-assignment as well as conflict resolution. The Coordinator shall chair all meetings of the Steering Committee, unless decided otherwise in a meeting of the Steering Committee. 14 / 47 JADECARE Consortium Agreement - Final version , 2020-10-26 6.3.2.2 Minutes of meetings Minutes of Steering Committee meetings, once accepted, shall be sent by the Coordinator to the General Assembly Members for information. 6.3.2.3 Tasks 6.3.2.3.1 The Steering Committee shall prepare the meetings, propose decisions and prepare the agenda of the General Assembly according to Section 6.3.1.2. 6.3.2.3.2 The Steering Committee shall seek a consensus among the Beneficiaries. 6.3.2.3.3 The Steering Committee shall be responsible for the proper execution and implementation of the decisions of the General Assembly. 6.3.2.3.4 The Steering Committee shall monitor the effective and efficient implementation of the Joint Action. 6.3.2.3.5 In addition, the Steering Committee shall collect information at least every 6 months on the progress of the Joint Action, examine that information to assess the compliance of the Joint Action with the Consortium Plan and, if necessary, propose modifications of the Consortium Plan to the General Assembly. 6.3.2.3.6 The Steering Committee shall be in charge of:  following up progress in each of the critical areas and the planning of tasks and activities;  monitoring the technical quality of the work and coordination between WP Leads;  conflict resolution;  establishment of mitigation plans to reduce the impact of potential risks;  effort/budget re-assignment;  constituting committees for matters that require specific attention (such as security, new technological issues, gender equality, etc.) and establishing working procedures for such committees;  supporting the Coordinator in preparing meetings with the Funding Authority and in preparing related data and deliverables;  preparing the content and timing of press releases and joint publications by the consortium or proposed by the Funding Authority in respect of the procedures of the Grant Agreement Article 29. 6.3.2.3.7 In the case of abolished tasks as a result of a decision of the General Assembly, the Steering Committee shall advise the General Assembly on ways to rearrange tasks and budgets of the Beneficiaries concerned. Such rearrangement shall take into consideration the legitimate commitments taken prior to the decisions, which cannot be cancelled. 15 / 47 JADECARE Consortium Agreement - Final version , 2020-10-26 6.4 Coordinator 6.4.1 The Coordinator shall be the intermediary between the Beneficiaries and the Funding Authority and shall perform all tasks assigned to it as described in the Grant Agreement and in this Consortium Agreement. 6.4.2 In particular, the Coordinator shall be responsible for:  monitoring compliance by the Beneficiaries with their obligations;  keeping the address list of Members and other contact persons updated and available;  collecting, reviewing to verify consistency and submitting reports, other deliverables (including financial statements and related certifications) and specific requested documents to the Funding Authority;  transmitting documents and information connected with the Joint Action to any other Beneficiaries concerned;  administering the financial contribution of the Funding Authority and fulfilling the financial tasks described in Section 7.3;  providing, upon request, the Beneficiaries with official copies or originals of documents that are in the sole possession of the Coordinator when such copies or originals are necessary for the Beneficiaries to present claims. Before sending any proposal for amendment to Grant Agreement to the EC on behalf of the Beneficiaries, the Coordinator will inform all Beneficiaries in advance and present the documents in question to those Beneficiaries that ask for it. The Coordinator will wait to receive the explicit acceptance of the Beneficiaries which shall not be unreasonably withheld. The terms and conditions of the signed documents are only binding for the Beneficiaries if their explicit acceptance have been given prior to the time of the signature. If no answer is received by the Coordinator from a Beneficiary before the deadline established in the communication sent, it will be assumed that such silent Beneficiary accepts the content of the amendment. If one or more of the Beneficiaries is late in submission of any Joint Action deliverable, the Coordinator may nevertheless submit the other ’Beneficiaries’ Joint Action deliverables and all other documents required by the Grant Agreement to the Funding Authority in time. 6.4.3 If the Coordinator fails in its coordination tasks, the General Assembly may propose to the Funding Authority to change the Coordinator. 6.4.4 The Coordinator shall not be entitled to act or to make legally binding declarations on behalf of any other Beneficiary or of the consortium, unless explicitly stated otherwise in the Grant Agreement or this Consortium Agreement. 6.4.5 The Coordinator shall not enlarge its role beyond the tasks specified in this Consortium Agreement and in the Grant Agreement. 16 / 47 JADECARE Consortium Agreement - Final version , 2020-10-26 6.5 Coordination Team KRONIKGUNE assumes the role of JA Coordinator, being the organization representing the JADECARE Consortium. It is responsible for the achievement of the JA goals and the contractual obligations towards the European Commission, and provides global scientific and technical leadership, quality assurance policy and overall coordination of the joint action. The Coordinator Team is formed by the JA Coordinator supported by the Scientific Coordinator, the Project Manager and the Financial Manager. 6.6 Work Package Lead (WPL) The WPL is performed by the Lead Beneficiary (LB), the Leading Executive Organization (LEO) and the co-Leading Executive Organisation. LEO and co-Leading Executive Organisation have the responsibility for day-to-day management and coordination of the activities included in their respective work packages as defined in the work plan, implement solutions for problems, supervise Task Leaders, produce the corresponding deliverables, identify risks as early as possible and follow them up, and report to the PM about the progress achieved against that planned. They are able to raise proposals to the SC regarding effort and budget redistribution, and re-assignment of roles and responsibilities within their respective WPs. WP participants meets at least once a month via tele- or web- conferencing. 6.7 Next Adopters Working Groups (NAWG) The NAWGs include local stakeholders in all the participating countries. A Next Adopters Working Group (NAWG) is created in each of the next adopter sites for the implementation of the Local Good Practices, led by the representative of the corresponding Competent Authority or Affiliated Entity. NAWGs are supported by the responsible of the original Good Practices as described in the transfer WPs (WP5-8). The NAWG includes a representative of health systems, healthcare professionals, community members and third sector. All members of each next adopter team shall meet regularly in order to share their experiences and learn from them, suggest improvements, receive and provide support, plan different measures, review objectives, and collect and deliver good practices. During these meetings, the Competent Authority or affiliated Entity representative shall inform the members of the team about the progress of the intervention in the other areas, highlighting any problematic situation or any issues raised. 6.8 Policy Board (PB) The PB is an external board composed by representatives of all Competent Authorities involved in JADECARE that are MoHs, national focal points for Health Programme at the European Commission (or other representatives of MSs identified by them) from other Member States from EU and EEA, and all other policy-oriented stakeholders that implementers will identify as important based on their sustainability-related analyses. The role of the Policy Board shall be to give input to sustainability plans from the focus of policy, and the definition of core messages to support evidence-based policy making with respect to sustainability of JADECARE results. The PB has a key role in guaranteeing the sustainability of the Joint Action and the impact after the end of the project. The Policy board shall be established and coordinated by WP4 Lead with support of the Coordination Team. 17 / 47 JADECARE Consortium Agreement - Final version , 2020-10-26 7 Section: Financial provisions 7.1 General Principles 7.1.1 Distribution of Financial Contribution The financial contribution of the Funding Authority to the Joint Action shall be distributed by the Coordinator according to:  the Consortium Plan,  the approval of reports by the Funding Authority, and  the provisions of payment in Section 7.3. A Beneficiary shall be funded only for its tasks carried out in accordance with the Consortium Plan. 7.1.2 Justifying Costs In accordance with its own usual accounting and management principles and practices, each Beneficiary shall be solely responsible for justifying its costs with respect to the Joint Action towards the Funding Authority. Neither the Coordinator nor any of the other Beneficiaries shall be in any way liable or responsible for such justification of costs towards the Funding Authority. Each Beneficiary will establish the necessary legal, administrative and/or operational arrangements with their Affiliated Entities to ensure the correct justification of the costs incurred. 7.1.3 Funding Principles A Beneficiary that spends less than its allocated share of the budget as set out in the Consortium Plan or implements less units than foreseen in the Consortium Plan will be funded in accordance with its actual duly justified eligible costs only. A Beneficiary that spends more than its allocated share of the budget as set out in the Consortium Plan will be funded only in respect of duly justified eligible costs up to an amount not exceeding that share. 7.1.4 Return of excess payments; receipts In any case of a Beneficiary having received excess payments, the Beneficiary has to return the relevant amount to the Coordinator without undue delay. In case a Beneficiary earns any receipt that is deductible from the total funding as set out in the Consortium Plan, the deduction is only directed toward the Beneficiary earning such income. The other Beneficiaries’ financial share of the budget shall not be affected by one Beneficiary’s receipt. In case the relevant receipt is more than the allocated share of the Beneficiary as set out in the Consortium Plan, the Beneficiary shall reimburse the funding reduction suffered by other Beneficiaries. 7.1.5 Financial Consequences of the termination of the participation of a Beneficiary A Beneficiary leaving the consortium shall refund all payments it has received except the amount of contribution accepted by the Funding Authority or another contributor. Furthermore, a Defaulting Beneficiary shall, within the limits specified in Section 5.2 of this Consortium Agreement, bear any reasonable and justifiable additional costs occurring to the other Beneficiaries in order to perform its and their tasks. 18 / 47 JADECARE Consortium Agreement - Final version , 2020-10-26 7.2 Budgeting The budget set out in the Consortium Plan shall be valued in accordance with the usual accounting and management principles and practices of the respective Beneficiaries. 7.3 Payments 7.3.1 Payments to Beneficiaries are the exclusive tasks of the Coordinator. In particular, the Coordinator shall:  Notify the Beneficiary concerned promptly of the date and composition of the amount transferred to its bank account, giving the relevant references.  Perform diligently its tasks in the proper administration of any funds and in maintaining financial accounts.  Undertake to keep the Funding Authority’s financial contribution to the Joint Action separated from its normal business accounts, its own assets and property, except if the Coordinator is a Public Body or is not entitled to do so due to statutory legislation.  With reference to Articles 16.2 and 16.3.2 of the Grant Agreement, no Beneficiary shall before the end of the Joint Action receive more than its allocated share of the maximum grant amount from which the amounts retained by the Funding Authority for the final payment have been deducted. 7.3.2 Payment schedule The payment schedule, which contains the transfer of pre-financing and interim payments to Beneficiaries, will be handled after receipt from the Funding Authority according to the following: The Beneficiaries agree that the Funding Authority´s total pre-financing will be paid once the Consortium Agreement has been signed by all beneficiaries. Funding of costs included in the Consortium plan will be paid to Beneficiaries after receipt from the Funding Authority without unjustified delay and in conformity with the provisions of the Grant Agreement. Costs accepted by the Funding Authority will be paid to the Beneficiary concerned. The Coordinator is entitled to withhold any payments due to a Beneficiary identified by a responsible Consortium Body to be in breach of its obligations under this Consortium Agreement or the Grant Agreement or to a Beneficiary which has not yet signed this Consortium Agreement. The Coordinator is entitled to recover any payments already paid to a Defaulting Beneficiary. The Coordinator is equally entitled to withhold payments to a Beneficiary when this is suggested by or agreed with the Funding Authority. 8 Section: Results 8.1 Ownership of Results Results are owned by the Beneficiary that generates them. 8.2 Joint ownership Joint ownership is governed by Grant Agreement Article 19.2 with the following additions: Unless otherwise agreed: 19 / 47 JADECARE Consortium Agreement - Final version , 2020-10-26 - each of the joint owners shall be entitled to use their jointly owned Results for non- commercial research activities on a royalty-free basis, and without requiring the prior consent of the other joint owner(s), and - each of the joint owners shall be entitled to otherwise Exploit the jointly owned Results and to grant non-exclusive licenses to third parties (without any right to sub-license), if the other joint owners are given: a) at least 45 calendar days advance notice with a right for the other joint owners to object hereto at the latest 15 days after receipt of such notice, but only if the objecting joint owner's legitimate academic or commercial interests are compromised; and b) if no objection is made within the time limit stated above, the permission is given by the other joint owners who each shall receive Fair and Reasonable compensation taking into account each joint owner's relative contribution to the jointly owned Results. 8.3 Transfer of Results 8.3.1 Each Beneficiary may transfer ownership of its own Results following the procedures of the Grant Agreement Article n°19. 8.3.2 It may identify specific third Beneficiaries it intends to transfer the ownership of its Results to in Attachment (2) to this Consortium Agreement. The other Beneficiaries hereby waive their right to prior notice and their right to object to a transfer to listed third Beneficiaries according to the Grant Agreement Article 19. 8.3.3 The transferring Beneficiary shall, however, at the time of the transfer, inform the other Beneficiaries of such transfer and shall ensure that the rights of the other Beneficiaries will not be affected by such transfer. Any addition to Attachment (2) after signature of this Agreement requires a decision of the General Assembly. 8.3.4 The Beneficiaries recognize that in the framework of a merger or an acquisition of an important part of its assets, it may be impossible under applicable EU and national laws on mergers and acquisitions for a Beneficiary to give the full 45 calendar days prior notice for the transfer as foreseen in the Grant Agreement. 8.3.5 The obligations above apply only for as long as other Beneficiaries still have - or still may request - Access Rights to the Results. 8.4 Dissemination 8.4.1 For the avoidance of doubt, nothing in this Section 8.4 has impact on the confidentiality obligations set out in Section 10. 20 / 47 JADECARE Consortium Agreement - Final version , 2020-10-26 8.4.2 Dissemination of own Results 8.4.2.1 During the Joint Action and for a period of 1 year after the end of the Joint Action, the dissemination of own Results by one or several Beneficiaries including but not restricted to publications and presentations, shall be governed by the procedure of Article 22 of the Grant Agreement subject to the following provisions. Prior notice of any planned publication shall be given to the other Beneficiaries at least 45 calendar days before the publication. Any objection to the planned publication shall be made in accordance with the Grant Agreement in writing to the Coordinator and to the Beneficiary or Beneficiaries proposing the dissemination within 30 calendar days after receipt of the notice. If no objection is made within the time limit stated above, the publication is permitted. 8.4.2.2 An objection is justified if (a) the protection of the objecting Beneficiary's Results would be adversely affected (b) the objecting Beneficiary's legitimate interests in relation to the Results would be significantly harmed. The objection has to include a precise request for necessary modifications. 8.4.2.3 If an objection has been raised the involved Beneficiaries shall discuss how to overcome the justified grounds for the objection on a timely basis (for example by amendment to the planned publication and/or by protecting information before publication) and the objecting Beneficiary shall not unreasonably continue the opposition if appropriate measures are taken following the discussion. 8.5 The objecting Beneficiary can request a publication delay of not more than 90 calendar days from the time it raises such an objection. After 90 calendar days, the publication is permitted, provided that reasonable modifications of the objecting Party have been implemented in the Publication as indicated by the objecting Party. 8.5.1 Dissemination of another Beneficiary’s unpublished Results A Beneficiary shall not include in any dissemination activity another Beneficiary's Results without obtaining the owning Beneficiary's prior written approval, unless they are already published, in which case, in addition, the owning Beneficiary has to be informed. The mere absence of an objection is not considered as an approval. 8.5.2 Cooperation obligations The Beneficiaries undertake to cooperate to allow the timely submission, examination, publication and defense of any dissertation or thesis for a degree that includes their Results subject to the confidentiality and publication provisions agreed in this Consortium Agreement. 8.5.3 Use of names, logos or trademarks Nothing in this Consortium Agreement shall be construed as conferring rights to use in advertising, publicity or otherwise the name of the Beneficiaries or any of their logos or trademarks without their prior written approval. 21 / 47 JADECARE Consortium Agreement - Final version , 2020-10-26 9 Section: Access Rights 9.1 General Principles 9.1.1 Each Beneficiary shall implement its tasks in accordance with the Consortium Plan and shall bear sole responsibility for ensuring that its acts within the Joint Action do not knowingly infringe Affiliated Entity property rights. 9.1.2 Any Access Rights granted expressly exclude any rights to sublicense unless expressly stated otherwise. 9.1.3 Access Rights shall be free of any administrative transfer costs. 9.1.4 Access Rights are granted on a non-exclusive basis. 9.1.5 Results and Background shall be used only for the purposes for which Access Rights to it have been granted. 9.1.6 All requests for Access Rights shall be made in writing. The granting of Access Rights may be made conditional on the acceptance of specific conditions aimed at ensuring that these rights will be used only for the intended purpose and that appropriate confidentiality obligations are in place. For the avoidance of doubt, this means that the owning Beneficiary may impose to the Beneficiary requesting an Access Right the execution of a separate license agreement, this separate license agreement should be in line with the Consortium Agreement. 9.1.7 The requesting Beneficiary must show that the Access Rights are needed. 9.2 Access Rights for implementation Access Rights to Results needed for the performance of the own work of a Beneficiary under the Joint Action shall be granted on a royalty-free basis. 9.3 Access Rights for Exploitation 9.3.1 Access Rights to Results Access Rights to Results if Needed for Exploitation of a Beneficiary's own Results shall be granted on a royalty-free basis. 9.3.2 Access Rights to Background if Needed for Exploitation of a Beneficiary’s own Results, including for research on behalf of an Affiliated Entity, shall be granted on Fair and Reasonable conditions. 22 / 47 JADECARE Consortium Agreement - Final version , 2020-10-26 9.3.3 A request for Access Rights may be made up to twelve months after the end of the Joint Action or, in the case of Section 9.6.2.1.2, after the termination of the requesting Beneficiary’s participation in the Joint Action. 9.4 Access Rights for Affiliated Entities Affiliated Entities have Access Rights under the conditions of the Grant Agreement Article 19 if they are identified in [Attachment 2 (Identified Affiliated Entities) to this Consortium Agreement]. Such Access Rights must be requested by the Affiliated Entity from the Beneficiary that holds the Results. Alternatively, the Beneficiary granting the Access Rights may individually agree with the Beneficiary requesting the Access Rights to have the Access Rights include the right to sublicense to the latter's Affiliated Entities [listed in Attachment 2]. Access Rights to Affiliated Entities shall be granted on Fair and Reasonable conditions and upon written bilateral agreement. Affiliated Entities which obtain Access Rights in return fulfil all confidentiality and other obligations accepted by the Beneficiaries under the Grant Agreement or this Consortium Agreement as if such Affiliated Entities were Beneficiaries. Access Rights may be refused to Affiliated Entities if such granting is contrary to the legitimate interests of the Beneficiary which owns the Results. Access Rights granted to any Affiliated Entity are subject to the continuation of the Access Rights of the Beneficiary to which it is affiliated, and shall automatically terminate upon termination of the Access Rights granted to such Beneficiary. Upon cessation of the status as an Affiliated Entity, any Access Rights granted to such former Affiliated Entity shall lapse. Further arrangements with Affiliated Entities may be negotiated in separate agreements. 9.5 Additional Access Rights The Beneficiaries agree to negotiate in good faith any additional Access Rights to Results as might be asked for by any Beneficiary, upon adequate financial conditions to be agreed. 9.6 Access Rights for Beneficiaries entering or leaving the consortium 9.6.1 New Beneficiaries entering the consortium As regards Results developed before the accession of the new Beneficiary, the new Beneficiary will be granted Access Rights on the conditions applying for Access Rights to Background. 23 / 47 JADECARE Consortium Agreement - Final version , 2020-10-26 9.6.2 Beneficiaries leaving the consortium 9.6.2.1 Access Rights granted to a leaving Beneficiary 9.6.2.1.1 Defaulting Beneficiary Access Rights granted to a Defaulting Beneficiary and such Beneficiary's right to request Access Rights shall cease immediately upon receipt by the Defaulting Beneficiary of the formal notice of the decision of the General Assembly to terminate its participation in the consortium. 9.6.2.1.2 Non-defaulting Beneficiary A non-defaulting Beneficiary leaving voluntarily and with the other Beneficiaries' consent shall have Access Rights to the Results developed until the date of the termination of its participation. It may request Access Rights within the period specified in Section 9.3.3. 9.6.2.2 Access Rights to be granted by any leaving Beneficiary Any Beneficiary leaving the Joint Action shall continue to grant Access Rights pursuant to the Grant Agreement and this Consortium Agreement as if it had remained a Beneficiary for the whole duration of the Joint Action. 9.7 Specific Provisions for Access Rights to Software For the avoidance of doubt, the general provisions for Access Rights provided for in this Section 9 are applicable also to Software. Beneficiaries’ Access Rights to Software do not include any right to receive source code or object code ported to a certain hardware platform or any right to receive respective Software documentation in any particular form or detail, but only as available from the Beneficiary granting the Access Rights. 10 Section: Non-disclosure of information 10.1 All information in whatever form or mode of communication, which is disclosed by a Beneficiary (the “Disclosing Beneficiary”) to any other Beneficiary (the “Recipient”) in connection with the Joint Action during its implementation and which has been explicitly marked as “confidential” at the time of disclosure, or when disclosed orally has been identified as confidential at the time of disclosure and has been confirmed and designated in writing within 15 calendar days from oral disclosure at the latest as confidential information by the Disclosing Beneficiary, is “Confidential Information”. 10.2 The Recipients hereby undertake in addition and without prejudice to any commitment on non-disclosure under the Grand Agreement, for a period of 4 years after the end of the Joint Action:  Not to use Confidential Information otherwise than for the purpose for which it was disclosed;  not to disclose Confidential Information without the prior written consent by the Disclosing Beneficiary; 24 / 47 JADECARE Consortium Agreement - Final version , 2020-10-26  to ensure that internal distribution of Confidential Information by a Recipient shall take place on a strict need-to-know basis; and  to return to the Disclosing Beneficiary, or destroy, on request all Confidential Information that has been disclosed to the Recipients including all copies thereof and to delete all information stored in a machine-readable form to the extent practically possible. The Recipients may keep a copy to the extent it is required to keep, archive or store such Confidential Information because of compliance with applicable laws and regulations or for the proof of on-going obligations provided that the Recipient comply with the confidentiality obligations herein contained with respect to such copy for as long as the copy is retained. 10.3 The recipients shall be responsible for the fulfilment of the above obligations on the part of their employees or Affiliated Entities involved in the Joint Action and shall ensure that they remain so obliged, as far as legally possible, during and after the end of the Joint Action and/or after the termination of the contractual relationship with the employee or Affiliated Entity. 10.4 The above shall not apply for disclosure or use of Confidential Information, if and in so far as the Recipient can show that:  the Confidential Information has become or becomes publicly available by means other than a breach of the Recipient’s confidentiality obligations;  the Disclosing Beneficiary subsequently informs the Recipient that the Confidential Information is no longer confidential;  the Confidential Information is communicated to the Recipient without any obligation of confidentiality by an Affiliated Entity who is to the best knowledge of the Recipient in lawful possession thereof and under no obligation of confidentiality to the Disclosing Beneficiary;  the disclosure or communication of the Confidential Information is foreseen by provisions of the Grant Agreement;  the Confidential Information, at any time, was developed by the Recipient completely independently of any such disclosure by the Disclosing Beneficiary;  the Confidential Information was already known to the Recipient prior to disclosure, or  the Recipient is required to disclose the Confidential Information in order to comply with applicable laws or regulations or with a court or administrative order, subject to the provision Section 10.7 hereunder. 10.5 The Recipient shall apply the same degree of care with regard to the Confidential Information disclosed within the scope of the Joint Action as with its own confidential and/or proprietary information, but in no case less than reasonable care. 10.6 Each Beneficiary shall promptly advise the other Beneficiary in writing of any unauthorised disclosure, misappropriation or misuse of Confidential Information after it becomes aware of such unauthorised disclosure, misappropriation or misuse. 25 / 47 JADECARE Consortium Agreement - Final version , 2020-10-26 10.7 If any Beneficiary becomes aware that it will be required, or is likely to be required, to disclose Confidential Information in order to comply with applicable laws or regulations or with a court or administrative order, it shall, to the extent it is lawfully able to do so, prior to any such disclosure  notify the Disclosing Beneficiary, and  comply with the Disclosing Beneficiary’s reasonable instructions to protect the confidentiality of the information. 11 Section: Miscellaneous 11.1 Attachments, inconsistencies and severability This Consortium Agreement consists of this core text and - Attachment 1 (Accession document). - Attachment 2 (Identified Affiliated Entities). In case the terms of this Consortium Agreement are in conflict with the terms of the Grant Agreement, the terms of the latter shall prevail. In case of conflicts between the attachments and the core text of this Consortium Agreement, the latter shall prevail. Should any provision of this Consortium Agreement become invalid, illegal or unenforceable, it shall not affect the validity of the remaining provisions of this Consortium Agreement. In such a case, the Beneficiaries concerned shall be entitled to request that a valid and practicable provision be negotiated that fulfils the purpose of the original provision. 11.2 No representation, partnership or agency Except as otherwise provided in Section 6.4.4, no Beneficiary shall be entitled to act or to make legally binding declarations on behalf of any other Beneficiary or of the consortium. Nothing in this Consortium Agreement shall be deemed to constitute a joint venture, agency, partnership, interest grouping or any other kind of formal business grouping or entity between the Beneficiaries. 11.3 Notices and other communication Any notice to be given under this Consortium Agreement shall be in writing to the addresses and recipients as listed in the most current address list kept by the Coordinator. Formal notices: If it is required in this Consortium Agreement (Sections 4.2, 9.6, 9.7 and 11.4) that a formal notice, consent or approval shall be given, such notice shall be signed by an authorised representative of a Beneficiary and shall either be served personally or sent by mail with recorded delivery. Other communication: Other communication between the Beneficiaries may also be affected by other means such as e-mail with acknowledgement of receipt, which fulfils the conditions of written form. 26 / 47 JADECARE Consortium Agreement - Final version , 2020-10-26 Any change of persons or contact details shall be notified immediately by the respective Beneficiary to the Coordinator. The address list shall be accessible to all Beneficiaries. 11.4 Assignment and amendments Except as set out in Section 8.3, no rights or obligations of the Beneficiaries arising from this Consortium Agreement may be assigned or transferred, in whole or in part, to any Affiliated Entity without the other Beneficiaries’ prior formal approval. Amendments and modifications to the text of this Consortium Agreement not explicitly listed in Section 6.3 require a separate written agreement to be signed among all Beneficiaries. 11.5 Mandatory national law Nothing in this Consortium Agreement shall be deemed to require a Beneficiary to breach any mandatory statutory law under which the Beneficiary is operating. 11.6 Language This Consortium Agreement is drawn up in English, which language shall govern all documents, notices, meetings, arbitral proceedings and processes relative thereto. 11.7 Applicable law This Consortium Agreement shall be construed in accordance with and governed by the laws of Belgium excluding its conflict of law provisions. 11.8 Settlement of disputes The Beneficiaries shall endeavor to settle their disputes amicably. The Beneficiaries agree that any dispute, controversy or claim arising under, out of or relating to this Consortium Agreement and any subsequent amendments of this Consortium Agreement, including, without limitation, its formation, validity, binding effect, interpretation, performance, breach or termination (a "Dispute") which cannot be solved amicably, shall first be submitted by the Beneficiaries to the Work Package Leader concerned. The Coordination Team may be involved in the conflict resolution if requested by the Work Package Leader. In case the Work Package Leader fails to reach an amicable agreement within 15 days from the date on which the Dispute was referred to it, the Dispute shall be submitted to the Steering Committee that will try to reach a solution by consensus within (15 days) from the date on which the Dispute was referred to it. Disputes which cannot be settled amicably shall be subject to the jurisdiction of the competent court in Brussels. 27 / 47 JADECARE Consortium Agreement - Final version , 2020-10-26 LIETUVOS RESPUBLIKOS SVEIKATOS APSAUGOS MINISTERIJA (LR SAM), Signature Name: Gitana Ratkiene Title: Ministry of Health of the Republic of Lithuania, Personal Health care Department, Primary health care and nursing Division. Adviser Date 40 / 47 JADECARE Consortium Agreement - Final version , 2020-10-26 Attachment 1: Accession document ACCESSION of a new Beneficiary to [Acronym of the Joint Action] Consortium Agreement, version […, YYYY-MM-DD] [OFFICIAL NAME OF THE NEW BENEFICIARY AS IDENTIFIED IN THE Grant Agreement] hereby consents to become a Beneficiary to the Consortium Agreement identified above and accepts all the rights and obligations of a Beneficiary starting [date]. [OFFICIAL NAME OF THE COORDINATOR AS IDENTIFIED IN THE Grant Agreement] hereby certifies that the consortium has accepted in the meeting held on [date] the accession of [the name of the new Beneficiary] to the consortium starting [date]. This Accession document has been done in 2 originals to be duly signed by the undersigned authorised representatives. [Date and Place] [INSERT NAME OF THE NEW BENEFICIARY] Signature(s) Name(s) Title(s) [Date and Place] [INSERT NAME OF THE COORDINATOR] Signature(s) Name(s) Title(s) 45 / 47 JADECARE Consortium Agreement - Final version , 2020-10-26 Attachment 2: List of Affiliated Entities  FUNDACION PARA LA FORMACION E INVESTIGACION SANITARIAS DE LA REGION DE MURCIA (FFIS), affiliated or linked to KG  FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD (FPS), affiliated or linked to KG  Servicio Cántabro de Salud (SCS), affiliated or linked to KG  GERENCIA REGIONAL DE SALUD DE CASTILLA Y LEON (SACYL), affiliated or linked to KG  CONSEJERIA DE SALUD y FAMILIAS DE LA JUNTA DE ANDALUCIA (CSFJA), affiliated or linked to KG  FUNDACION INSTITUTO DE INVESTIGACION MARQUES DE VALDECILLA (IDIVAL), affiliated or linked to KG  CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER (IDIBAPS), affiliated or linked to KG  AGENCIA DE QUALITAT I AVALUACIO SANITARIES DE CATALUNYA (AQUAS), affiliated or linked to KG  SERVICIO MURCIANO DE SALUD (SMS), affiliated or linked to KG  ZAVOD ZA JAVNO ZDRAVSTVO FEDERACIJEBOSNE I HERCEGOVINE (ZZJZFBIH), affiliated or linked to MCA  MINISTARSTVO ZDRAVLJA I SOCIJALNE ZASTITE REPUBLIKE SRPSKE (MHSw- RS), affiliated or linked to MCA  HRVATSKI ZAVOD ZA ZDRAVSTVENO OSIGURANJE (CHIF), affiliated or linked to CIPH  FAKULTNI NEMOCNICE OLOMOUC (UHO), affiliated or linked to MZCR  REGION SYDDANMARK (RSD), affiliated or linked to RND  SIHTASUTUS VILJANDI HAIGLA (VH), affiliated or linked to MSAE  BAYERISCHES LANDESAMT FUR GESUNDHEIT UND LEBENSMITTELSICHERHEIT (LGL), affiliated or linked to BAGSFI  ZTG ZENTRUM FUR TELEMATIK IM GESUNDHEITSWESEN GMBH (ZTG-GmBH), affiliated or linked to BAGSFI  ARISTOTELIO PANEPISTIMIO THESSALONIKIS (AUTH), affiliated or linked to 4THYPE  SEMMELWEIS EGYETEM (SU-HSMTC), affiliated or linked to AEEK  JAHN FERENC DEL-PESTI KORHAZ ES RENDELOINTEZET (JFDPK), affiliated or linked to AEEK 46 / 47 JADECARE Consortium Agreement - Final version , 2020-10-26  AZIENDA ULSS 4 VENETO ORIENTALE (PROMIS), affiliated or linked to AGENAS  REGIONE LOMBARDIA (LOMBARDIA), affiliated or linked to AGENAS  AZIENDA UNITA SANITARIA LOCALE UMBRIA 1 (UMBRIA), affiliated or linked to AGENAS  MINISTERO DELLA SALUTE (MhH), affiliated or linked to AGENAS  REGIONE MARCHE (MARCHE), affiliated or linked to AGENAS  AGENZIA REGIONALE DI SANITA (TOSCANA), affiliated or linked to AGENAS  AZIENDA SANITARIA LOCALE NA 2 NORD (ASL NA2), affiliated or linked to AGENAS  BERNU KLINISKA UNIVERSITATES SLIMNICA VALSTS SIA (CCUH), affiliated or linked to NVD  SPMS - SERVICOS PARTILHADOS DO MINISTERIO DA SAUDE EPE (SPMS), affiliated or linked to ACSS  UNIVERSIDADE NOVA DE LISBOA (ENSP/NOVA), affiliated or linked to ACSS  ZAVOD ZA ZDRAVSTVENO ZAVAROVANJE SLOVENIJE THE HEALTH INSURANCE INSTITUTE OF SLOVENIA (ZZZS), affiliated or linked to NIJZ 47 / 47
Allikas: Sotsiaalministeerium dokumendiregister →
dokumendiregister.eeAsutusedEesti avalike dokumendiregistrite otsing · nimistu.ee andmetel